|
PF-184563 is a potent, selective non-peptidic antagonist of the V1a receptor. The compound was discovered by Pfizer in its Sandwich, Kent research center, as a potential treatment for dysmenorrhoea, an indication for which V1a antagonists have shown efficacy. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「PF-184563」の詳細全文を読む スポンサード リンク
|